» Articles » PMID: 27090092

The Natural History of Subclinical Hyperthyroidism in Graves' Disease: The Rule of Thirds

Overview
Journal Thyroid
Date 2016 Apr 20
PMID 27090092
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There is little information regarding the natural history of subclinical hyperthyroidism (SH) due to Graves' disease (GD).

Methods: A prospective analysis was conducted of patients with SH due to GD between 2007 and 2013 with at least 12 months of follow-up. SH was diagnosed if serum thyrotropin (TSH) was below the laboratory reference range (0.4-4.0 mIU/L) and when thyroid hormones were normal. GD was confirmed by either a raised TSH receptor antibody (TRAb) level or uniform uptake on Technetium scan.

Results: Forty-four patients (89% female, 16% current smokers, and 5% with active Graves' orbitopathy) were diagnosed with SH due to GD. Over the follow-up period (median 32 months), approximately one third (34%) of the cohort progressed to overt hyperthyroidism, one third (34%) normalized their thyroid function, slightly less than one third (30%) remained in the SH state, while one person became hypothyroid. Multivariate regression analysis showed that older age and positive antithyroid peroxidase (TPO) antibody status had a positive association with risk of progression to overt hyperthyroidism, with hazard ratios of 1.06 ([confidence interval (CI) 1.02-1.10], p < 0.01) per year and 10.15 ([CI 1.83-56.23], p < 0.01), respectively, independent of other risk factors including, smoking, TRAb levels at diagnosis, and sex.

Conclusions: A third each of patients with SH due to GD progress, normalize, or remain in the SH state. Older people and those with positive anti-TPO antibodies have a higher risk of progression of the disease. These novel data need to be verified and confirmed in larger cohorts and over longer periods of follow-up.

Citing Articles

Change in newly diagnosed Graves' disease phenotype between the twentieth and the twenty-first centuries: meta-analysis and meta-regression.

Ippolito S, Cusini C, Lasalvia P, Gianfagna F, Veronesi G, Gallo D J Endocrinol Invest. 2020; 44(8):1707-1718.

PMID: 33346898 PMC: 8285314. DOI: 10.1007/s40618-020-01479-z.


Management of Graves Thyroidal and Extrathyroidal Disease: An Update.

Kahaly G J Clin Endocrinol Metab. 2020; 105(12).

PMID: 32929476 PMC: 7543578. DOI: 10.1210/clinem/dgaa646.


2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy.

Muller I, Moran C, Lecumberri B, Decallonne B, Robertson N, Jones J Eur Thyroid J. 2019; 8(4):173-185.

PMID: 31602359 PMC: 6738237. DOI: 10.1159/000500881.


2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism.

Kahaly G, Bartalena L, Hegedus L, Leenhardt L, Poppe K, Pearce S Eur Thyroid J. 2018; 7(4):167-186.

PMID: 30283735 PMC: 6140607. DOI: 10.1159/000490384.


Pesticide Use and Incident Hypothyroidism in Pesticide Applicators in the Agricultural Health Study.

Shrestha S, Parks C, Goldner W, Kamel F, Umbach D, Ward M Environ Health Perspect. 2018; 126(9):97008.

PMID: 30256155 PMC: 6375417. DOI: 10.1289/EHP3194.